Bengaluru, July 9 -- Leading brokerage house, Macquarie, has maintained its "Outperform" rating on Sun Pharma and assigned a target price of Rs 2,135 per share, signalling an upside potential of 28 percent from its Tuesday closing price of Rs 1,672.50 per share.

The brokerage mentioned that Sun Pharma has a low US exposure, which is that it accumulates 31 percent of its revenue from the US market, followed by 33 percent from India. This makes it less vulnerable to US tariffs as the majority of Indian pharmaceutical companies depend on US exports, which account for a large chunk of money.

The company reported over 16,200 crore in revenue from the US in FY25, which grew at a CAGR of 9.06 percent over the past five years. And on a year-on...